Loading...
Genomma Lab Internacional, S.A.B. de C.V.
GNMLF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$1.09
$0.00(0.00%)
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Financial Performance & Income Statement Overview
Review Genomma Lab Internacional, S.A.B. de C.V.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
12.99%
↑ 12.99%
Operating Income Growth
20.33%
↑ 20.33%
Net Income Growth
37.63%
↑ 37.63%
Operating Cash Flow Growth
35.01%
↑ 35.01%
Operating Margin
22.64%
↑ 22.64%
Gross Margin
63.42%
↑ 63.42%
Net Profit Margin
7.21%
↑ 7.21%
ROE
12.09%
↑ 12.09%
ROIC
20.81%
↑ 20.81%
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Income Statement & Financial Overview
Review Genomma Lab Internacional, S.A.B. de C.V.'s (GNMLF) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $4.41B | $4.67B | $5.09B | $4.65B |
| Cost of Revenue | $1.64B | $1.72B | $1.82B | $1.67B |
| Gross Profit | $2.77B | $2.94B | $3.27B | $2.98B |
| Gross Profit Ratio | $0.63 | $0.63 | $0.64 | $0.64 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $1.72B | $1.84B | $2.08B | $1.92B |
| Operating Expenses | $1.81B | $1.93B | $2.14B | $1.99B |
| Total Costs & Expenses | $3.45B | $3.65B | $3.96B | $3.67B |
| Interest Income | $28.25M | $36.80M | $25.35M | $9.007M |
| Interest Expense | $220.10M | $248.37M | $230.25M | $208.56M |
| Depreciation & Amortization | $97.02M | $121.19M | $88.53M | $59.84M |
| EBITDA | $1.02B | $968.71M | $1.25B | $1.13B |
| EBITDA Ratio | $0.23 | $0.21 | $0.25 | $0.24 |
| Operating Income | $960.62M | $1.01B | $1.13B | $983.28M |
| Operating Income Ratio | $0.22 | $0.22 | $0.22 | $0.21 |
| Other Income/Expenses (Net) | -$259.45M | -$413.97M | -$196.56M | -$140.61M |
| Income Before Tax | $701.17M | $599.15M | $932.26M | $842.67M |
| Income Before Tax Ratio | $0.16 | $0.13 | $0.18 | $0.18 |
| Income Tax Expense | $202.45M | $125.66M | $272.20M | $211.03M |
| Net Income | $498.72M | $473.49M | $660.06M | $631.64M |
| Net Income Ratio | $0.11 | $0.10 | $0.13 | $0.14 |
| EPS | $0.51 | $0.50 | $0.66 | $0.67 |
| Diluted EPS | $0.51 | $0.50 | $0.66 | $0.67 |
| Weighted Avg Shares Outstanding | $973.79M | $977.75M | $1.000B | $942.75M |
| Weighted Avg Shares Outstanding (Diluted) | $973.79M | $977.75M | $1.000B | $942.75M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan